A THERAPEUTIC DNA VACCINE IN NONHUMAN PRIMATE AGAINST CHAGAS DISEASE

针对非人类灵长类动物的恰加斯病治疗性 DNA 疫苗

• 批准号: 7562393
• 负责人: ERIC DUMONTEIL
• 金额: $ 1.4万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562393
• 关键词: Adverse effects; Animals; Blood; Brazil; Cardiac; Cessation of life; Chagas Disease; Chronic Phase of Disease; Colon; Computer Retrieval of Information on Scientific Projects Database; DNA; DNA Vaccines; Disease; Ear; Esophageal; Funding; Genus Cola; Grant; Heart failure; Individual; Infection; Institution; Liver; Mexico; Nitrofurans; Parasites; Patients; Pharmaceutical Preparations; Pilot Projects; Polymerase Chain Reaction; Primates; Research; Research Personnel; Resources; Risk; Schedule; Skeletal Muscle; Source; Spleen; Tail; Testing; Therapeutic; Tissues; Trypanosoma; United States National Institutes of Health; Vaccines; Week; Whole Blood; Work; day; nonhuman primate; vaccination schedule

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chagas disease, or American Trypanosomiasis, is caused by the protozoan parasite Trypanosoma cruiz. An estimated 16-18 million people are infected and close to 100 million people are at risk of infection from southern Brazil to Mexico. During the chronic phases of the disease, infected individuals undergo extensive tissue damage, primarily cardiac tissue but also spleen, liver, skeletal muscle, colon and esophageal with this tissue damage progressively leading to cardiac failure and death. Over 20,000 deaths per year are attributed to this disease. Treatment of infected patients relies on nitrofurans but these drugs are of little efficacy and have serious side effects. Nine animals (n=6 on Pilot project and n=3 on Gorgas) were inoculated subcutaneously on 1/17/07 with T.cruzi parasites supplied by Dr. Yabsley at UGA. Ear/tail blood smears have been collected weekly since inoculation. To date, no parasites have been found in these smears. Beginning three weeks ago, whole blood has been sent to Dr. Dorn at Loyola to be tested for parasite DNA. PCR results were not clean but five animals have consistently shown bands positive for T.cruzi DNA. I am working on sending her na¿ve blood to determine if the other bands are primate DNA or some other contamination. Meanwhile, none of the scheduled vaccinations have occurred. A total of three DNA vaccines spaced 30 days apart were scheduled to begin last month.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 恰加斯病或美洲锥虫病是由原生动物寄生虫克鲁兹锥虫引起的。 从巴西南部到墨西哥，估计有 16-1800 万人被感染，近 1 亿人面临感染风险。 在疾病的慢性阶段，感染者会遭受广泛的组织损伤，主要是心脏组织，但也包括脾、肝、骨骼肌、结肠和食管，这种组织损伤逐渐导致心力衰竭和死亡。 每年有超过 20,000 人死于这种疾病。 感染患者的治疗依赖于硝基呋喃，但这些药物疗效甚微且副作用严重。 2007 年 1 月 17 日，九只动物（试点项目中 n = 6 只，Gorgas 中 n = 3 只）皮下接种了佐治亚大学 Yabsley 博士提供的 T.cruzi 寄生虫。 自接种以来每周收集耳/尾血涂片。 迄今为止，这些涂片中尚未发现寄生虫。 从三周前开始，全血已被送往洛约拉的多恩博士进行寄生虫 DNA 检测。 PCR 结果并不明确，但有 5 只动物始终显示 T.cruzi DNA 呈阳性条带。 我正在努力输送她的纯血以确定其他条带是否是灵长类 DNA 或其他污染。 与此同时，预定的疫苗接种都没有进行。总共三种 DNA 疫苗计划于上个月开始，间隔 30 天。